A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 01 Jun 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesalazine (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms CAMP-III

Most Recent Events

24 May 2012 Additional lead trial investigator (Herman Ellman) identified as reported by ClinicalTrials.gov.
24 May 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
24 May 2012 Actual patient number is 39 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight